When is targeted therapy recommended for gastrointestinal stromal tumour?

A gastrointestinal stromal tumour, or GIST, is assessed using scans, biopsy findings, tumour location, size, spread and molecular testing. The mutation result can help identify which targeted medicine is likely to interfere with the tumour's growth signal. Treatment may be considered before surgery to reduce or control a tumour, after surgery when recurrence risk is a concern, or when the tumour has spread or returned. The choice and dose can change if scans show growth or side effects affect daily life.

Ask whether mutation testing has been completed and how it changes the treatment choice. Discuss whether the aim is to make surgery easier, reduce recurrence risk or control disease that cannot be removed. Tell the team about bleeding, abdominal symptoms, heart problems, liver conditions and all medicines. Ask how scans, blood tests and side effects will be followed.

Seek prompt advice for black or bloody stools, vomiting blood, severe abdominal pain, persistent vomiting, yellowing of the skin, swelling, unusual bleeding or sudden breathlessness. Emergency help is appropriate for heavy bleeding, collapse, severe chest pain or severe breathing difficulty.

What mutation does my tumour have? Is surgery possible now or after treatment? What outcome are we aiming for? Which symptoms suggest bleeding or a serious side effect?